ImmuCell Q3 revenue surges; swings to profit

By Reuters News


Overview

  • Animal health biologics firm's Q3 revenue rose 46% yr/yr, aided by distributor restocking timing

  • Q3 net income swung to profit from year-ago loss


Outlook

  • Company investing in capacity expansion and colostrum sourcing to meet future demand

  • Company expects to sign new $3 mln line of credit in Q4 2026

  • Company sees favorable inventory levels heading into peak season


Result Drivers

  • DISTRIBUTOR RESTOCKING - Revenue growth benefited from the absence of distributor restocking headwinds that had hurt Q3 2025 sales

  • VOLUME AND SALES ACTIVITY - Co said distributor out-the-door volume grew 18% yr/yr, with broad-based growth across sales territories and product lines supported by increased sales activity and customer acquisition

  • HIGHER PRICING AND MANUFACTURING EXECUTION - Gross margin rose due to higher pricing and improved manufacturing execution, partially offset by shift of some product development expenses to cost of goods sold


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Product Sales

$8.04 mln

Q3 EPS

$0.10

Q3 Net Income

$953,000

Q3 Basic EPS

$0.10

Q3 Operating Expenses

$2.60 mln

Q3 Pretax Profit

$936,000


Reuters Recommended Reads

  • Nov 10 - Scholar Rock posts first product revenue after ISEMBYLD launch

  • Nov 12 - Fennec Pharma Q3 product sales rise 56% on PEDMARK demand

  • Nov 12 - Pelthos Q3 Zelsuvmi revenue jumps 114%, net loss narrows


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk